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Introduction 
 Amyotrophic Lateral Sclerosis (ALS), commonly 
known as “Lou Gehrig’s Disease,” is a fatal neurodegenera-
tive disorder characterized by the slow degeneration of the 
motor neurons (MNs) of the entire human body, including, 
but not limited to, the MNs of the cerebral cortex, spinal 
cord and limb, axial and respiratory muscles. ALS is an 
adult-onset, rapidly progressive disease, killing 50% of pa-
tients within 2 and a half years of symptom onset. There 
are two types of disease onset, Limb-onset, which is char-
acterized by degeneration of upper and lower motor neu-
rons (UMN and LMN) identified by weakness, fasciculations 
and spasticity of the limbs, and Bulbar-onset, degeneration 
of tongue muscles causing weakness and fasciculations in 
the tongue as well as spastic dysarthria and dysphagia. 
Eventually, no matter the type of onset, the motor neuron 
degeneration spreads throughout the body resulting in 
paralysis of the limbs and eventually the diaphragm, caus-
ing respiratory distress and ultimately death (Kiernan, et al. 
2011). 
ALS has been categorized into two classes, familial ALS, 
which is genetic and presented through a Mendelian 
pattern of inheritance, accounts for 5-10% of people with 
ALS, and Sporadic ALS which accounts for the remaining 
90% (Kiernan, et al. 2011). 
 At present, the etiology remains complex and un-
resolved and has confounded scientists over the century. 
As a result, finding a treatment for ALS has proved to be 
extremely challenging.  The etiology seems to be multifac-
eted with many genetic and molecular factors contributing 
directly and indirectly to the degeneration of motor neu-
rons, including gene mutations, neurotoxins, glutamate-
induced excitotoxicity, and structural abnormalities of the 
mitochondrion, sodium potassium pump and axonal struc-
tures. Mutations in SOD1 gene generates a toxic gain of 
function of SOD1 enzyme, formation of free radicals and 
formation of  aggregates due to improper folding of the 
SOD1 protein, resulting in impaired motor neuron function 
and neuron death (Kiernan, et al. 2011). The SOD1 gene, 
which accounts for 20% of familial ALS, is of significant im-
portance because it can transduce mice into effective ALS 
models for stem cell therapy and other research (Gurney, 
et al. 1994). 
To date, only one drug, Riluzole, remains effective in 
treating ALS symptoms, by inhibiting glutamate receptors 
and slowing the disease progression by 3-6 months.  This 
unfortunate lack of a significant cure or treatment may be 
a result of the inadequacy of diagnostic tests. By the time a 
patient is diagnosed with ALS, many of their motor neu-
rons have allready died, and their muscles atrophied. Since 
ALS can only be diagnosed once clinical symptoms appear, 
there is no early detection and therefor, no early preven-
tion (Kiernan, et al. 2011).    
 Stem cells, however, provide an astonishing and 
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effective alternative. They can accomplish what Riluzole 
cannot, providing hope for a future regenerative cure for 
neurodegenerative diseases. Stem cells are cells capable of 
giving rise to new cells of the same type or to different cell 
types through the process of differentiation.  Modern re-
search has discovered that stem cells can be induced into 
neurons, which can regenerate neurons, reestablish neural 
connections and protect the remaining neurons from fur-
ther degeneration when transplanted into mouse or hu-
man ALS models and patients (Miles, et al. 2004; Nizzardo, 
et al. 2013; Peljto, et al. 2010; Son, et al. 2011; Takahashi, 
Yamanka, 2006; Takahashi, et al. 2007; Umbach, et al. 
2012; Vierbuchen, et al. 2010; Wichterle, et al. 2002; Xu, et 
al. 2009; Yao, et al. 2013) If the safety and efficiency of 
stem cells can be determined, the progression of ALS can 
be halted and reversed, rather than just slowed down. 
Stem cells derived from embryos, called Embryonic Stem 
cells (ESC) can differentiate in to the three germ layers, 
ectoderm, mesoderm and endoderm and then be forced 
through specialized transcription factors or signals to 
differentiate into functioning neurons in vitro and in vivo 
(Miles, et al. 2004; Peljto, et al. 2010; Umbach, et al. 2012; 
Wichterle, et al. 2002). However, ESCs provide an ethical 
issue because the embryo is sacrificed in exchange for 
stem cells. Therefor a modern approach was created by 
inducing differentiated stem cells, including post-natal and 
adult stem cells, into a pluripotent state, which can then 
be induced into neurons and other cells through transcrip-
tion factors with ESC-like efficiency (Nizzardo, et al. 2013; 
Takahashi, Yamanka, 2006; Takahashi, et al. 2007; Yao, et 
al. 2013).  However, the induction of a stem cell into a plu-
ripotent state requires the use of oncogenes and tumor-
igenic factors which can be preserved in the induced neu-
ron state. These factors can produce malignant tumors in 
vivo, a challenging clinical hurdle to overcome (Lee, et al. 
2013). The most recent research has been devoted to di-
rectly converting stem cells into neurons, skipping the plu-
ripotent state and avoiding the formation of potentially 
malignant neoplasms (Son, et al. 2011; Vierbuchen, et al. 
2010). These three approaches each have advantages and 
limitations, which will be discussed in further detail, and 
provide a promising hope for a future cure for ALS. 
 
 
Embryonic Stem Cells 
 To begin the process of generating motor neurons 
from ESC we must understand the developmental stages 
and the signaling characteristics of motor neurons from 
the ectoderm. Ectodermal cells develop into a neural pro-
genitor state through the regulating signals, bone morpho-
genetic protein (BMP), fibroblast growth factor (FGF) and 
Wnt. These signals play a vital role during development of 
neural progenitor cells by regulating cell-to-cell interac-
tions and controlling the activation or deactivation of spe-
cific genes (Wilson, Edlund, 2001). These neural progenitor 
cells, which are characterized by the expression of neural 
biomarkers, Neuronal Nuclei (NeuN), Sex determining re-
gion Y- box 1(Sox1), and Neuronal Class III β –Tubulin 
(TuJ1), can then differentiate into all classifications of neu-
rons through the help of specific transcription factors and 
signals. Through the action of Sonic hedgehog (Shh) signal-
ing these neural progenitor cells are transformed to a pro-
genitor motor neuron (pMN) domain, which are destined 
to the fate of spinal motor neurons. These cells in the pMN 
domain are characterized by the expression of Pax6, 
Nkx6.1 and Olig2 proteins which each have a role in the 
differentiation of various spinal motor neurons (Wichterle, 
et al. 2002). Additionally, these factors direct the expres-
sion of Hb9, a transcription factor found in MNs.  
 
Figure 1: A: Insertion of green fluorescent protein (eGFP) in the 
Hb9 promoter. B-G: eGFP expression in an embryonic mouse, 
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indicative of Hb9 transcription factor and presence of spinal 
motor neurons (source Wichterle, et al. 2002). 
 
Hb9 is commonly used to identify motor neuron presence 
in vivo and in vitro research, through the genetic insertion 
of Green Fluorescent Protein (GFP) in the Hb9 promoter 
site (Figure 1). The GFP will be expressed and visually 
viewed if Hb9 is expressed, a factor indicative of motor 
neuron presence (Wichterle, et al. 2002). 
 
 Wichterle et al. began the transformation of ESC 
into motor neurons by isolating ESCs from a mouse em-
bryo and growing them in culture to produce embryoid 
bodies (EBs). These EBs produced very few of the neural 
progenitor state factors, Sox1, NeuN and TuJ1. In contrast, 
when retinoic acid (RA) was added to the culture, many 
neurons were detected, evident by Sox1, NeuN and TuJ1 
expression. To determine whether RA exposed EBs can be 
generated into motor neurons specifically, the expression 
of pMN domain proteins, Pax6, Nkx6.1 and Olig2, was 
monitored. Few of these proteins were detected and these 
cells continued to differentiate mostly into interneurons, 
instead of motor neurons, demonstrating that RA alone 
cannot sufficiently induce motor neurons. Therefore, Shh 
was added to RA-exposed EBs, to generate pMN domain 
cells.  After the addition of Shh, expression of Pax6, Nkx6.1 
and Olig2 proteins and Hb9 transcription factor was ob-
served, indicating the development of motor neurons. To 
further prove the involvement and necessity of Shh, a 
function blocking anti-Hh antibody, which impairs the func-
tion of Shh, was added to the RA-exposed EBs. No Hb9 was 
observed under these conditions. However, when in-
creased levels of Shh were added, the amount of Hb9 in-
creased significantly, in a “concentration dependent manor 
(Wichterle, et al. 2002),” indicating a RA and Shh depend-
ent motor neuronal pathway (Figure 2). 
 
Figure 2: A: generation of motor neurons from the ectoderm of 
an embryo, requiring the involvement of RA and Shh B: expres-
sion of Hb9 in ESC exposed to: Shh alone, RA alone, RA with 
function blocking Hh antibody and RA with Shh. Motor neurons, 
indicated by white dots, are found in minor amount in RA only 
culture and in abundance in RA and Shh culture. Absence of 
motor neurons occur in the absence of RA and in the presence 
of function blocking Hh antibody. C: quantity of GFP/Hb9 cells 
grown in RA and different quantities of Shh. -1000 refers to cells 
grown without RA.  (Source: Wichterle, et al. 2002). 
  
 Survival and differentiation of these induced motor 
neurons was tested in the spinal cord of a mouse in vivo. 
ESC-derived motor neurons were grafted onto a mouse 
spinal cord. After 3 days, GFP was detected in the ventral 
regions of the spinal cord, indicating the ability of these 
induced motor neurons to survive and differentiate in a 
living model (Wichterle, et al. 2002). The positioning, tra-
jectory and extension of ESC-derived motor neurons in 
vivo was then compared with normal motor neuron behav-
ior in embryos. Normal extension along the ventral roots of 
the spinal cord was detected by use of GFP. Additionally, 
the motor neurons extended to appropriate muscles, de-
pending on where it was grafted, cervical, thoracic and 
lumbar segments of the cord (Wichterle, et al. 2002).  In 
another study, two types of ESC-derived MNs, median co-
lumnar motor neurons (MMC), which are normally found 
medially in the spinal cord and innervate axial muscles, and 
lateral columnar motor neurons (LMC), which are posi-
tioned laterally and innervate limb muscles, were mixed 
together and transplanted in the spinal cord of a mouse. 
MMC and LMC were found to aggregate in their appropri-
ate medial and lateral regions, next to other motor neu-
rons of their type. In addition to settling in their appropri-
ate regions, the MNs projected along the appropriate 
pathways, the LMC extending to the limb musculature and 
the MMC extending to axial musculature (Figure 3) (Peljto, 
et al. 2010). This implies that ESC-derived MNs can popu-
late all levels of the spinal cord and project along the prop-
er trajectories to specified muscles in vivo. 
 
 These studies demonstrate the possibility of gen-
erating motor neurons from ESCs and their ability to posi-
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effective alternative. They can accomplish what Riluzole 
cannot, providing hope for a future regenerative cure for 
neurodegenerative diseases. Stem cells are cells capable of 
giving rise to new cells of the same type or to different cell 
types through the process of differentiation.  Modern re-
search has discovered that stem cells can be induced into 
neurons, which can regenerate neurons, reestablish neural 
connections and protect the remaining neurons from fur-
ther degeneration when transplanted into mouse or hu-
man ALS models and patients (Miles, et al. 2004; Nizzardo, 
et al. 2013; Peljto, et al. 2010; Son, et al. 2011; Takahashi, 
Yamanka, 2006; Takahashi, et al. 2007; Umbach, et al. 
2012; Vierbuchen, et al. 2010; Wichterle, et al. 2002; Xu, et 
al. 2009; Yao, et al. 2013) If the safety and efficiency of 
stem cells can be determined, the progression of ALS can 
be halted and reversed, rather than just slowed down. 
Stem cells derived from embryos, called Embryonic Stem 
cells (ESC) can differentiate in to the three germ layers, 
ectoderm, mesoderm and endoderm and then be forced 
through specialized transcription factors or signals to 
differentiate into functioning neurons in vitro and in vivo 
(Miles, et al. 2004; Peljto, et al. 2010; Umbach, et al. 2012; 
Wichterle, et al. 2002). However, ESCs provide an ethical 
issue because the embryo is sacrificed in exchange for 
stem cells. Therefor a modern approach was created by 
inducing differentiated stem cells, including post-natal and 
adult stem cells, into a pluripotent state, which can then 
be induced into neurons and other cells through transcrip-
tion factors with ESC-like efficiency (Nizzardo, et al. 2013; 
Takahashi, Yamanka, 2006; Takahashi, et al. 2007; Yao, et 
al. 2013).  However, the induction of a stem cell into a plu-
ripotent state requires the use of oncogenes and tumor-
igenic factors which can be preserved in the induced neu-
ron state. These factors can produce malignant tumors in 
vivo, a challenging clinical hurdle to overcome (Lee, et al. 
2013). The most recent research has been devoted to di-
rectly converting stem cells into neurons, skipping the plu-
ripotent state and avoiding the formation of potentially 
malignant neoplasms (Son, et al. 2011; Vierbuchen, et al. 
2010). These three approaches each have advantages and 
limitations, which will be discussed in further detail, and 
provide a promising hope for a future cure for ALS. 
 
 
Embryonic Stem Cells 
 To begin the process of generating motor neurons 
from ESC we must understand the developmental stages 
and the signaling characteristics of motor neurons from 
the ectoderm. Ectodermal cells develop into a neural pro-
genitor state through the regulating signals, bone morpho-
genetic protein (BMP), fibroblast growth factor (FGF) and 
Wnt. These signals play a vital role during development of 
neural progenitor cells by regulating cell-to-cell interac-
tions and controlling the activation or deactivation of spe-
cific genes (Wilson, Edlund, 2001). These neural progenitor 
cells, which are characterized by the expression of neural 
biomarkers, Neuronal Nuclei (NeuN), Sex determining re-
gion Y- box 1(Sox1), and Neuronal Class III β –Tubulin 
(TuJ1), can then differentiate into all classifications of neu-
rons through the help of specific transcription factors and 
signals. Through the action of Sonic hedgehog (Shh) signal-
ing these neural progenitor cells are transformed to a pro-
genitor motor neuron (pMN) domain, which are destined 
to the fate of spinal motor neurons. These cells in the pMN 
domain are characterized by the expression of Pax6, 
Nkx6.1 and Olig2 proteins which each have a role in the 
differentiation of various spinal motor neurons (Wichterle, 
et al. 2002). Additionally, these factors direct the expres-
sion of Hb9, a transcription factor found in MNs.  
 
Figure 1: A: Insertion of green fluorescent protein (eGFP) in the 
Hb9 promoter. B-G: eGFP expression in an embryonic mouse, 
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indicative of Hb9 transcription factor and presence of spinal 
motor neurons (source Wichterle, et al. 2002). 
 
Hb9 is commonly used to identify motor neuron presence 
in vivo and in vitro research, through the genetic insertion 
of Green Fluorescent Protein (GFP) in the Hb9 promoter 
site (Figure 1). The GFP will be expressed and visually 
viewed if Hb9 is expressed, a factor indicative of motor 
neuron presence (Wichterle, et al. 2002). 
 
 Wichterle et al. began the transformation of ESC 
into motor neurons by isolating ESCs from a mouse em-
bryo and growing them in culture to produce embryoid 
bodies (EBs). These EBs produced very few of the neural 
progenitor state factors, Sox1, NeuN and TuJ1. In contrast, 
when retinoic acid (RA) was added to the culture, many 
neurons were detected, evident by Sox1, NeuN and TuJ1 
expression. To determine whether RA exposed EBs can be 
generated into motor neurons specifically, the expression 
of pMN domain proteins, Pax6, Nkx6.1 and Olig2, was 
monitored. Few of these proteins were detected and these 
cells continued to differentiate mostly into interneurons, 
instead of motor neurons, demonstrating that RA alone 
cannot sufficiently induce motor neurons. Therefore, Shh 
was added to RA-exposed EBs, to generate pMN domain 
cells.  After the addition of Shh, expression of Pax6, Nkx6.1 
and Olig2 proteins and Hb9 transcription factor was ob-
served, indicating the development of motor neurons. To 
further prove the involvement and necessity of Shh, a 
function blocking anti-Hh antibody, which impairs the func-
tion of Shh, was added to the RA-exposed EBs. No Hb9 was 
observed under these conditions. However, when in-
creased levels of Shh were added, the amount of Hb9 in-
creased significantly, in a “concentration dependent manor 
(Wichterle, et al. 2002),” indicating a RA and Shh depend-
ent motor neuronal pathway (Figure 2). 
 
Figure 2: A: generation of motor neurons from the ectoderm of 
an embryo, requiring the involvement of RA and Shh B: expres-
sion of Hb9 in ESC exposed to: Shh alone, RA alone, RA with 
function blocking Hh antibody and RA with Shh. Motor neurons, 
indicated by white dots, are found in minor amount in RA only 
culture and in abundance in RA and Shh culture. Absence of 
motor neurons occur in the absence of RA and in the presence 
of function blocking Hh antibody. C: quantity of GFP/Hb9 cells 
grown in RA and different quantities of Shh. -1000 refers to cells 
grown without RA.  (Source: Wichterle, et al. 2002). 
  
 Survival and differentiation of these induced motor 
neurons was tested in the spinal cord of a mouse in vivo. 
ESC-derived motor neurons were grafted onto a mouse 
spinal cord. After 3 days, GFP was detected in the ventral 
regions of the spinal cord, indicating the ability of these 
induced motor neurons to survive and differentiate in a 
living model (Wichterle, et al. 2002). The positioning, tra-
jectory and extension of ESC-derived motor neurons in 
vivo was then compared with normal motor neuron behav-
ior in embryos. Normal extension along the ventral roots of 
the spinal cord was detected by use of GFP. Additionally, 
the motor neurons extended to appropriate muscles, de-
pending on where it was grafted, cervical, thoracic and 
lumbar segments of the cord (Wichterle, et al. 2002).  In 
another study, two types of ESC-derived MNs, median co-
lumnar motor neurons (MMC), which are normally found 
medially in the spinal cord and innervate axial muscles, and 
lateral columnar motor neurons (LMC), which are posi-
tioned laterally and innervate limb muscles, were mixed 
together and transplanted in the spinal cord of a mouse. 
MMC and LMC were found to aggregate in their appropri-
ate medial and lateral regions, next to other motor neu-
rons of their type. In addition to settling in their appropri-
ate regions, the MNs projected along the appropriate 
pathways, the LMC extending to the limb musculature and 
the MMC extending to axial musculature (Figure 3) (Peljto, 
et al. 2010). This implies that ESC-derived MNs can popu-
late all levels of the spinal cord and project along the prop-
er trajectories to specified muscles in vivo. 
 
 These studies demonstrate the possibility of gen-
erating motor neurons from ESCs and their ability to posi-
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tion and project correctly in a host spinal cord. The ques-
tion still remains if these motor neurons can function as 
normal motor neurons. In order to use stem cell therapy to 
treat neurodegenerative disorders, ESC-derived MNs must 
be able to establish connections, release neurotrans-
mitters, respond to neurotransmitters, and generate action 
potentials.   
 MNs containing GFP were prepared through ESC 
exposure to RA and Shh. Several tests were then conduct-
ed to assess MN properties. To determine whether the 
MNs can connect to muscles, the ESC-derived MNs were 
placed with myotubes, muscle progenitor cells found in 
embryo. After 1 day GFP-labeled MNs extended across the 
myotubes. Additionally, greater than 95% of the GFP la-
beled MNs that migrated onto the myotubes, expressed 
ChAT, an enzyme involved in the formation of the neuro-
transmitter, acetylcholine, indicating the possible ability of 
the MNs to release cholinergic neurotransmitters 
(Wichterle, et al. 2002). To establish whether the MNs can 
send functional neurotransmitters and thereby form a 
functional connection with muscles, the MNs were cul-
tured together with myotubes and analyzed. After one day, 
acetylcholine (ACh) receptors, which take up ACh to stimu-
late muscle contraction, were found on myotubes adjacent 
to the axons of the ESC-derived MNs ( figure 4). These ACh 
receptors were not observed in the absence of these mo-
tor neurons, indicating the ability of ESC-derived MNs to 
form functional connections with muscles (Miles, et al. 
2004). 
 
Figure 4: Ai: axons of GFP-ESC-derived MN. Aii: ACh receptors 
on myotubes (arrows). Aiii: merged picture of axon and ACh 
receptor. (Source Miles, et al. 2004). 
 
 The effect of neurotransmitters on the ESC-derived 
MNs was then tested to demonstrate whether GABA, glu-
tamatergic and glycine receptors were present on the MNs 
and whether their corresponding neurotransmitters can 
generate a post synaptic action potential on the motor 
neuron. GABA and glycine, are characteristically inhibitory 
neurotransmitters in the mature state, however in the em-
bryonic and early postnatal stages they act as excitatory 
neurotransmitters. Glutamate is an excitatory neurotrans-
mitter which normally generates action potentials in motor 
neurons. Voltage clamp recording was used to read the 
membrane potential as the experiment was conducted. In 
all 3 cases action potentials in the MN membranes were 
generated when bathed in the neurotransmitters. GABA, 
glycine and glutamate generated an excitatory post synap-
tic potential typical of embryonic MNs, demonstrating the 
ability of these ESC-derived MNs to respond appropriately 
to neurotransmitters (Miles, et al. 2004). 
 
 Next, the possibility of generating multiple trains 
of action potentials was determined. It seems that the ac-
tion potential development of ESC-derived MNs develop 
similarly to MNs in embryo. In early embryonic stages only 
single trains of action potentials can be fired. In later stag-
es, however, repetitive trains of action potentials can be 
generated. Similar results were found in ESC-derived MNs, 
using a current-clamp technique to insert pulses of cur-
rent.  During the first 3 days in culture, only single action 
potentials could be induced. By the third day, however, 
repetitive trains of action potentials were detected in 52 
out of 61 ESC-derived MNs (See Figure 6) (Miles, et al. 
2004). 
 These findings indicate the possibility of gener-
ating motor neurons from embryonic stem cells and the 
ability of these ESC-derived MNs to function as normal mo-
tor neurons. Although these findings are remarkable, there 
is a strong controversy regarding the source of the stem 
cells, since human embryos have to be sacrificed to apply 
this therapy to humans. Studies were conducted to deter-
mine whether a less controversial method of inducing mo-
tor neurons could be employed. The primary alternative 
method discovered was the induction of pluripotency of a 
differentiated, non-embryonic stem cell.   
 
Induced Pluripotent Stem Cells: 
 Pluripotency is an undifferentiated cell state. A cell 
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that maintains pluripotency can differentiate into any cell 
type with the aid of specified factors and signals.  By 
means of specialized transcription factors, differentiated 
stem cells destined to a certain cell fate can be repro-
grammed into a pluripotent stem cell state. These induced 
pluripotent stem cells (iPSCs) can then differentiate into 
any cell, including motor neurons, through a similar pro-
cess to the induction of ESC-derived MNs. Fibroblasts, 
differentiated stem cells destined to produce connective 
tissue components, such as collagen and other materials, 
are most commonly used. Fibroblasts can be isolated from 
the adult human body as well as embryos, enabling the 
generation of patient-specific cells from a noncontroversial 
source. With this research, a patient’s own cells can be 
generated into a pluripotent state and eventually into mo-
tor neurons that can be transplanted more safely and effi-
ciently in to a host since they will not be rejected by the 
patient’s immune system (Lee, et al. 2013). The patient will 
not have to take Immunosuppressant drugs, because the 
body will recognize the cells as its own, reducing the risk of 
infections after transplantation.  
 To reprogram a cell into a pluripotent state, genes 
found in the regulation and maintenance of pluripotency in 
embryos were added to a culture of mouse embryonic fi-
broblast cells. A combination of 24 possible genes were 
found to induce colonies similar in morphology to ESCs 
(Figure 6A). To narrow down the candidates, each gene 
was individually removed to determine whether or not 
each gene had a positive effect on the induction of pluripo-
tency. The withdrawal of four genes, Oct3/4, klf4, Sox2 and 
c-Myc, resulted in the absence of any colony formation. 
The addition of these four genes alone to fibroblast culture 
generated colonies more similar in morphology to ESCs 
than the combination of 24. The absence of any one of 
these genes produced colonies of different morphology 
than ESCs (Figure 7B), indicating the individual necessity of 
each of these 4 genes in the renovation of fibroblasts into 
an ESC-like pluripotent state (Takahashi, Yamanka, 
2006).AB 
 To determine the pluripotency of these iPSCs re-
programmed from fibroblasts by 4 factors, they were in-
jected into mice and monitored. Teratomas consisting all 
three germ layers, which further differentiated into neural 
tissues, muscle tissue, cartilage, epithelium and other ma-
terials, were observed (Takahashi, Yamanka, 2006). The 
development of these tumors denotes the ability to create 
pluripotent stem cells, from differentiated cells, that are 
identical to ESCs in morphology and pluripotency. These 
studies were similarly applied to adult human fibroblasts 
which were successfully induced into a pluripotent state 
with comparable efficiency to mouse embryonic fibroblasts 
(Takahashi, et al. 2007). 
 To examine the possibility of reprogramming ALS-
patient specific cells, an ALS mouse model was prepared by 
inducing a mouse with the mutant SOD1 gene, initiating 
motor neuron degeneration in the mouse (Gurney, et al. 
1994; Yao, et al. 2013). Fibroblast cells were then isolated 
from the tail of the SOD1-mutated mouse and introduced 
to the four transcription factors, Oct3/4, klf4, Sox2 and c-
Myc. Expression of ESC markers, such as specialized tran-
scription factors, were observed in the iPSCs, indicating 
a  successful reprogramming of fibroblasts into an undiffer-
entiated state. To confirm whether the iPSCs could be gen-
erated into motor neurons with a similar efficiency to ESC-
derived motor neurons, RA and Shh were added to the 
iPSCs. After the addition of RA, ~95% of the iPSC expressed 
the neural marker Tuj1. Shh was then added to induce a 
motor neuron fate. ~85% of these MNs expressed ChAT, 
the enzymatic precursor for ACh neurotransmitter and 
~24% expressed Hb9.  Whole-cell patch clamp technique 
was used to determine the electrical potential of these 
induced MNs. Multiple trains of action potentials were 
generated suggesting the ability of these induced MN to 
function normally (Yao, et al. 2013). 
 
 To assess the therapeutic potential of using iPSC to 
treat ALS, neural stem cells (NSCs), generated from iPSCs 
from human somatic fibroblasts, were delivered to SOD1-
mutated mice. The NSCs were treated with RA and Shh to 
induce motor neurons and injected into the cerebral spinal 
fluid. They were injected intrathecally or intravenously, 
rather than direct intraspinal transplantation, to minimize 
the invasiveness of the therapy and maximize safety. GFP 
was inserted in the NSCs to trace their trajectory. Analysis 
of the spine and GFP suggested that the NSCs integrated in 
appropriate regions of the spinal cord, especially in great 
quantities in regions of active neuron degeneration.  In 
both cases of delivery, survival of mice were significantly 
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tion and project correctly in a host spinal cord. The ques-
tion still remains if these motor neurons can function as 
normal motor neurons. In order to use stem cell therapy to 
treat neurodegenerative disorders, ESC-derived MNs must 
be able to establish connections, release neurotrans-
mitters, respond to neurotransmitters, and generate action 
potentials.   
 MNs containing GFP were prepared through ESC 
exposure to RA and Shh. Several tests were then conduct-
ed to assess MN properties. To determine whether the 
MNs can connect to muscles, the ESC-derived MNs were 
placed with myotubes, muscle progenitor cells found in 
embryo. After 1 day GFP-labeled MNs extended across the 
myotubes. Additionally, greater than 95% of the GFP la-
beled MNs that migrated onto the myotubes, expressed 
ChAT, an enzyme involved in the formation of the neuro-
transmitter, acetylcholine, indicating the possible ability of 
the MNs to release cholinergic neurotransmitters 
(Wichterle, et al. 2002). To establish whether the MNs can 
send functional neurotransmitters and thereby form a 
functional connection with muscles, the MNs were cul-
tured together with myotubes and analyzed. After one day, 
acetylcholine (ACh) receptors, which take up ACh to stimu-
late muscle contraction, were found on myotubes adjacent 
to the axons of the ESC-derived MNs ( figure 4). These ACh 
receptors were not observed in the absence of these mo-
tor neurons, indicating the ability of ESC-derived MNs to 
form functional connections with muscles (Miles, et al. 
2004). 
 
Figure 4: Ai: axons of GFP-ESC-derived MN. Aii: ACh receptors 
on myotubes (arrows). Aiii: merged picture of axon and ACh 
receptor. (Source Miles, et al. 2004). 
 
 The effect of neurotransmitters on the ESC-derived 
MNs was then tested to demonstrate whether GABA, glu-
tamatergic and glycine receptors were present on the MNs 
and whether their corresponding neurotransmitters can 
generate a post synaptic action potential on the motor 
neuron. GABA and glycine, are characteristically inhibitory 
neurotransmitters in the mature state, however in the em-
bryonic and early postnatal stages they act as excitatory 
neurotransmitters. Glutamate is an excitatory neurotrans-
mitter which normally generates action potentials in motor 
neurons. Voltage clamp recording was used to read the 
membrane potential as the experiment was conducted. In 
all 3 cases action potentials in the MN membranes were 
generated when bathed in the neurotransmitters. GABA, 
glycine and glutamate generated an excitatory post synap-
tic potential typical of embryonic MNs, demonstrating the 
ability of these ESC-derived MNs to respond appropriately 
to neurotransmitters (Miles, et al. 2004). 
 
 Next, the possibility of generating multiple trains 
of action potentials was determined. It seems that the ac-
tion potential development of ESC-derived MNs develop 
similarly to MNs in embryo. In early embryonic stages only 
single trains of action potentials can be fired. In later stag-
es, however, repetitive trains of action potentials can be 
generated. Similar results were found in ESC-derived MNs, 
using a current-clamp technique to insert pulses of cur-
rent.  During the first 3 days in culture, only single action 
potentials could be induced. By the third day, however, 
repetitive trains of action potentials were detected in 52 
out of 61 ESC-derived MNs (See Figure 6) (Miles, et al. 
2004). 
 These findings indicate the possibility of gener-
ating motor neurons from embryonic stem cells and the 
ability of these ESC-derived MNs to function as normal mo-
tor neurons. Although these findings are remarkable, there 
is a strong controversy regarding the source of the stem 
cells, since human embryos have to be sacrificed to apply 
this therapy to humans. Studies were conducted to deter-
mine whether a less controversial method of inducing mo-
tor neurons could be employed. The primary alternative 
method discovered was the induction of pluripotency of a 
differentiated, non-embryonic stem cell.   
 
Induced Pluripotent Stem Cells: 
 Pluripotency is an undifferentiated cell state. A cell 
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that maintains pluripotency can differentiate into any cell 
type with the aid of specified factors and signals.  By 
means of specialized transcription factors, differentiated 
stem cells destined to a certain cell fate can be repro-
grammed into a pluripotent stem cell state. These induced 
pluripotent stem cells (iPSCs) can then differentiate into 
any cell, including motor neurons, through a similar pro-
cess to the induction of ESC-derived MNs. Fibroblasts, 
differentiated stem cells destined to produce connective 
tissue components, such as collagen and other materials, 
are most commonly used. Fibroblasts can be isolated from 
the adult human body as well as embryos, enabling the 
generation of patient-specific cells from a noncontroversial 
source. With this research, a patient’s own cells can be 
generated into a pluripotent state and eventually into mo-
tor neurons that can be transplanted more safely and effi-
ciently in to a host since they will not be rejected by the 
patient’s immune system (Lee, et al. 2013). The patient will 
not have to take Immunosuppressant drugs, because the 
body will recognize the cells as its own, reducing the risk of 
infections after transplantation.  
 To reprogram a cell into a pluripotent state, genes 
found in the regulation and maintenance of pluripotency in 
embryos were added to a culture of mouse embryonic fi-
broblast cells. A combination of 24 possible genes were 
found to induce colonies similar in morphology to ESCs 
(Figure 6A). To narrow down the candidates, each gene 
was individually removed to determine whether or not 
each gene had a positive effect on the induction of pluripo-
tency. The withdrawal of four genes, Oct3/4, klf4, Sox2 and 
c-Myc, resulted in the absence of any colony formation. 
The addition of these four genes alone to fibroblast culture 
generated colonies more similar in morphology to ESCs 
than the combination of 24. The absence of any one of 
these genes produced colonies of different morphology 
than ESCs (Figure 7B), indicating the individual necessity of 
each of these 4 genes in the renovation of fibroblasts into 
an ESC-like pluripotent state (Takahashi, Yamanka, 
2006).AB 
 To determine the pluripotency of these iPSCs re-
programmed from fibroblasts by 4 factors, they were in-
jected into mice and monitored. Teratomas consisting all 
three germ layers, which further differentiated into neural 
tissues, muscle tissue, cartilage, epithelium and other ma-
terials, were observed (Takahashi, Yamanka, 2006). The 
development of these tumors denotes the ability to create 
pluripotent stem cells, from differentiated cells, that are 
identical to ESCs in morphology and pluripotency. These 
studies were similarly applied to adult human fibroblasts 
which were successfully induced into a pluripotent state 
with comparable efficiency to mouse embryonic fibroblasts 
(Takahashi, et al. 2007). 
 To examine the possibility of reprogramming ALS-
patient specific cells, an ALS mouse model was prepared by 
inducing a mouse with the mutant SOD1 gene, initiating 
motor neuron degeneration in the mouse (Gurney, et al. 
1994; Yao, et al. 2013). Fibroblast cells were then isolated 
from the tail of the SOD1-mutated mouse and introduced 
to the four transcription factors, Oct3/4, klf4, Sox2 and c-
Myc. Expression of ESC markers, such as specialized tran-
scription factors, were observed in the iPSCs, indicating 
a  successful reprogramming of fibroblasts into an undiffer-
entiated state. To confirm whether the iPSCs could be gen-
erated into motor neurons with a similar efficiency to ESC-
derived motor neurons, RA and Shh were added to the 
iPSCs. After the addition of RA, ~95% of the iPSC expressed 
the neural marker Tuj1. Shh was then added to induce a 
motor neuron fate. ~85% of these MNs expressed ChAT, 
the enzymatic precursor for ACh neurotransmitter and 
~24% expressed Hb9.  Whole-cell patch clamp technique 
was used to determine the electrical potential of these 
induced MNs. Multiple trains of action potentials were 
generated suggesting the ability of these induced MN to 
function normally (Yao, et al. 2013). 
 
 To assess the therapeutic potential of using iPSC to 
treat ALS, neural stem cells (NSCs), generated from iPSCs 
from human somatic fibroblasts, were delivered to SOD1-
mutated mice. The NSCs were treated with RA and Shh to 
induce motor neurons and injected into the cerebral spinal 
fluid. They were injected intrathecally or intravenously, 
rather than direct intraspinal transplantation, to minimize 
the invasiveness of the therapy and maximize safety. GFP 
was inserted in the NSCs to trace their trajectory. Analysis 
of the spine and GFP suggested that the NSCs integrated in 
appropriate regions of the spinal cord, especially in great 
quantities in regions of active neuron degeneration.  In 
both cases of delivery, survival of mice were significantly 
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extended. Intrathecally administered NSCs extended sur-
vival by ~10 days in all 24 mice in comparison to vehicle 
treated control SOD1-mutated mice and all 25 intrave-
nously treated mice survived ~23 days longer than vehicle 
treated control mice (Figure 7B and D). Although the sur-
vival extension seems very limited, it is statistically signifi-
cant and importantly, the extension remained steady in all 
the mice. Additionally, in a rotarod test, which evaluates 
neuromuscular function, NSC treated mice had a much 
higher rotarod functional outcome, indicating improved 
neuromuscular function (Figure 7A and C) (Nizzardo, et al.)  
 
Figure 5: A: comparison of Rotarod function in control mice 
and after intrathecal delivery. B: survival comparison between 
control and NSC intrathecally treated mice. C: comparison of 
Rotarod function in control mice and after intravenous delivery.  
D: survival comparison between control and NSC intravenously 
treated mice. (Source: Nizzardo, et al. 2013) Further studies 
were conducted to determine whether the induced motor neu-
rons transplanted can prevent further MN degeneration. The 
number of motor neurons was counted after 140 days in both 
control and stem cell treated mice. Mice treated with stem cells 
contained 40% more motor neurons than control mice, a very 
significant difference. Additionally, axonal density was pre-
served by 50% in stem cell treated mice while significant reduc-
tion was observed in control mice (Nizzardo, et al. 2013). These 
differences indicate the ability of induced MNs generated from 
iPSCs to protect against further motor neuron degeneration, 
thereby indicating the possibility of stem cell therapy to halt the 
disease progression of ALS. 
 
 
Clinical Hurdle for iPSCs: 
 
 While inducing pluripotency offers a noncontro-
versial and comparable alternative to ESCs, there is one 
chief clinical hurdle crucial to overcome. The process of 
inducing pluripotecy in differentiated stem cells requires 
the use of oncogenes. Genes such as Klf4, c-Myc and oth-
ers, which are central to inducing pluripotency, are funda-
mentally interconnected with the networks of benign and 
malignant tumor formation. The oncogenic network in-
cludes proliferation, differentiation and other properties 
that are major factors in pluripotency (Lee, et al. 2013). In 
fact, the way researchers detect pluripotency is by in-
jecting these iPSCs into mice where they form teratomas 
(Lee, et al. 2013; Takashi, Yamanka, 2006; Takashi, et al. 
2007; Yao, et al. 2013). The induction of pluripotency can 
cause malignant tumors by inducing genetic aberrations 
associated with tumorigenesis.  Deletions in tumor-
suppressor genes and activation of oncogenes by integra-
tion of transcription factors, such as Myc, are some exam-
ples of how the induction of pluripotency causes potential-
ly malignant neoplasms (Figure 8). 
 
 Besides for Myc, transcription factors such as Oct4, 
Klf4 and other core pluripotency factors are associated 
with tumorgenicity. These factors contain the possibility of 
maintaining their oncogenic tendency and causing malig-
nant neoplasms when transplanted in humans (Lee, et al. 
2013). To ensure patient protection, the clinical expression 
of these oncogenes will have to be researched further. 
Other options have to be explored to guarantee the safest 
and most efficient process of introducing stem cells into a 
human patient. 
Direct Reprogramming of Stem Cells into Motor neurons: 
In the face of obstacles such as ethical controversy and tu 
morigenic potential of ESCs and iPSCs respectively, re-
searchers have searched for other methods to apply stem 
cell therapy to treat ALS.  Direct reprogramming of somatic 
stem cells into motor neurons, skipping the pluripotent 
state, seems to be an ideal alternative and considerable 
research has been devoted to this plight. 
Vierbuchen et al. describes the process of directly repro-
gramming fibroblasts into neurons. Both mouse embryonic 
fibroblasts and mouse post natal fibroblasts were used to 
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ensure that both somatic and embryonic stem cells express 
similar efficiency. Five factors, prepared from an original 
pool of 19 were isolated based on their positive role in in-
ducing neural development, morphology and activity in 
fibroblasts.  Patch-clamp recording was used to identify 
whether action potentials could be generated in these in-
duced neurons (iNs).  A significant quantity of iNs, 85.1% , 
could elicit action potentials when induced with current. 
Additionally, iNs were responsive to GABA, glutamine and 
other excitatory neurotransmitters, indicating properly 
functioning receptor sites. iNs were placed into an existing 
neural network in vitro to determine whether the cells 
could integrate into complex neural networks. After 7 days, 
normal neuronal behavior was observed (Vierbuchen, et al. 
2010). This suggests the capability of iNs to integrate into 
and cooperate with the complex human neural network, a 
critical factor in human stem cell therapy. 
To directly induce a more specified subtype of neurons, 
such as a motor neurons, transcription factors that induce 
motor neuron identity in normal embryonic development 
were applied first to mouse embryonic fibroblasts, and 
later to human-derived fibroblasts. Eight candidate factors, 
responsible for various developmental stages of MNs, in 
addition to 3 of the 5 general neural transcription factors, 
described previously, were inserted into mouse embryonic 
fibroblasts. Hb9-GFP was used to indicate motor neuron 
presence. Seven factors were deemed necessary to gener-
ate induced motor neurons (iMNs).  Using a patch-clamp 
technique, the resting membrane potential was found to 
be -49.5mV, very similar to ESC-derived MNs, which is -
50.5mV. Single and multiple trains of action potentials 
were elicited using a current-clamp technique in 90% of 
iMNs. The ability of iMNs to respond to typical inhibitory 
and excitatory neurotransmitters was then tested by expo-
sure to GABA, glycine and glutamate. The iMNs elicited 
normal functioning inhibitory and excitatory action poten-
tials upon contact with these neurotransmitters, indicating 
functional response of iMNs to neurotransmitters (Son, et 
al. 2011). 
 To determine the capability of iMNs to form func-
tional synapses with muscles, called neuromuscular junc-
tions, and to stimulate muscle contraction by release of 
ACh, iMNs and myotubes were co-cultured. Remarkably, 
the iMNs extended along the myotubes and after several 
days began inducing rhythmic contractions in the myo-
tubes. To determine whether the contractions were 
caused by ACh, curare was added to the culture. Curare is 
an antagonist of ACh and will inhibit ACh from binding to 
the ACh receptor site and stimulating muscle contrac-
tion.  After the curare was added the contractions stopped, 
indicating the ability of iMNs to develop and dispatch func-
tional ACh neurotransmitters capable of stimulating muscle 
contraction.  iMNs were then transplanted into the spinal 
cord of chick embryos to determine whether these cells 
can migrate to appropriate regions, survive and maintain 
function in vivo. Using Hb9-GFP, proper migration was ob-
served in the spinal cord of the embryo. Additionally, 80% 
of iMNs extended their axons out of the spine toward the 
musculature. The same methods were applied to human 
fibroblasts with similar results (Son, et al. 2011). These 
findings indicate the similarity of iMNs to ESC-derived MNs 
and the capability of MNs to function normally both in 
vitro and in vivo. 
 These studies determined the ability of differenti-
ated cells to be directly converted into specific subclasses 
of neurons, including motor neurons, skipping the induced 
pluripotent state. The use of oncogenes and tumorigenic 
factors are avoided, because the fibroblasts are not re-
quired to pass through an undifferentiated, ESC-like state.   
 
Results 
  
 In this study, 3 different stem cell therapies were 
presented and discussed, embryonic stem cells, induced 
pluripotent stem cells and direct reprogramming of differ-
entiated cells into neurons. All three therapies demonstrat-
ed the ability to produce functional motor neurons from 
stem cells in vitro and some in vivo (Miles, et al. 2004; Niz-
zardo, et al. 2013; Peljto, et al. 2010; Son, et al. 2011; 
Takahashi, Yamanka, 2006; Takahashi, et al. 2007; Um-
bach, et al. 2012; Vierbuchen, et al. 2010; Wichterle, et al. 
2002; Xu, et al. 2009; Yao, et al. 2013). Embryonic stem 
cells can successfully generate functional motor neurons 
using factors and signals found in normal embryonic devel-
opment (Miles, et al. 2004; Peljto, et al. 2010; Umbach, et 
al. 2012; Wichtelle, et al. 2002). Because of its ethical con-
troversy alternative methods are being researched. How-
ever, ESC-derived motor neurons remains a model for oth-
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extended. Intrathecally administered NSCs extended sur-
vival by ~10 days in all 24 mice in comparison to vehicle 
treated control SOD1-mutated mice and all 25 intrave-
nously treated mice survived ~23 days longer than vehicle 
treated control mice (Figure 7B and D). Although the sur-
vival extension seems very limited, it is statistically signifi-
cant and importantly, the extension remained steady in all 
the mice. Additionally, in a rotarod test, which evaluates 
neuromuscular function, NSC treated mice had a much 
higher rotarod functional outcome, indicating improved 
neuromuscular function (Figure 7A and C) (Nizzardo, et al.)  
 
Figure 5: A: comparison of Rotarod function in control mice 
and after intrathecal delivery. B: survival comparison between 
control and NSC intrathecally treated mice. C: comparison of 
Rotarod function in control mice and after intravenous delivery.  
D: survival comparison between control and NSC intravenously 
treated mice. (Source: Nizzardo, et al. 2013) Further studies 
were conducted to determine whether the induced motor neu-
rons transplanted can prevent further MN degeneration. The 
number of motor neurons was counted after 140 days in both 
control and stem cell treated mice. Mice treated with stem cells 
contained 40% more motor neurons than control mice, a very 
significant difference. Additionally, axonal density was pre-
served by 50% in stem cell treated mice while significant reduc-
tion was observed in control mice (Nizzardo, et al. 2013). These 
differences indicate the ability of induced MNs generated from 
iPSCs to protect against further motor neuron degeneration, 
thereby indicating the possibility of stem cell therapy to halt the 
disease progression of ALS. 
 
 
Clinical Hurdle for iPSCs: 
 
 While inducing pluripotency offers a noncontro-
versial and comparable alternative to ESCs, there is one 
chief clinical hurdle crucial to overcome. The process of 
inducing pluripotecy in differentiated stem cells requires 
the use of oncogenes. Genes such as Klf4, c-Myc and oth-
ers, which are central to inducing pluripotency, are funda-
mentally interconnected with the networks of benign and 
malignant tumor formation. The oncogenic network in-
cludes proliferation, differentiation and other properties 
that are major factors in pluripotency (Lee, et al. 2013). In 
fact, the way researchers detect pluripotency is by in-
jecting these iPSCs into mice where they form teratomas 
(Lee, et al. 2013; Takashi, Yamanka, 2006; Takashi, et al. 
2007; Yao, et al. 2013). The induction of pluripotency can 
cause malignant tumors by inducing genetic aberrations 
associated with tumorigenesis.  Deletions in tumor-
suppressor genes and activation of oncogenes by integra-
tion of transcription factors, such as Myc, are some exam-
ples of how the induction of pluripotency causes potential-
ly malignant neoplasms (Figure 8). 
 
 Besides for Myc, transcription factors such as Oct4, 
Klf4 and other core pluripotency factors are associated 
with tumorgenicity. These factors contain the possibility of 
maintaining their oncogenic tendency and causing malig-
nant neoplasms when transplanted in humans (Lee, et al. 
2013). To ensure patient protection, the clinical expression 
of these oncogenes will have to be researched further. 
Other options have to be explored to guarantee the safest 
and most efficient process of introducing stem cells into a 
human patient. 
Direct Reprogramming of Stem Cells into Motor neurons: 
In the face of obstacles such as ethical controversy and tu 
morigenic potential of ESCs and iPSCs respectively, re-
searchers have searched for other methods to apply stem 
cell therapy to treat ALS.  Direct reprogramming of somatic 
stem cells into motor neurons, skipping the pluripotent 
state, seems to be an ideal alternative and considerable 
research has been devoted to this plight. 
Vierbuchen et al. describes the process of directly repro-
gramming fibroblasts into neurons. Both mouse embryonic 
fibroblasts and mouse post natal fibroblasts were used to 
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ensure that both somatic and embryonic stem cells express 
similar efficiency. Five factors, prepared from an original 
pool of 19 were isolated based on their positive role in in-
ducing neural development, morphology and activity in 
fibroblasts.  Patch-clamp recording was used to identify 
whether action potentials could be generated in these in-
duced neurons (iNs).  A significant quantity of iNs, 85.1% , 
could elicit action potentials when induced with current. 
Additionally, iNs were responsive to GABA, glutamine and 
other excitatory neurotransmitters, indicating properly 
functioning receptor sites. iNs were placed into an existing 
neural network in vitro to determine whether the cells 
could integrate into complex neural networks. After 7 days, 
normal neuronal behavior was observed (Vierbuchen, et al. 
2010). This suggests the capability of iNs to integrate into 
and cooperate with the complex human neural network, a 
critical factor in human stem cell therapy. 
To directly induce a more specified subtype of neurons, 
such as a motor neurons, transcription factors that induce 
motor neuron identity in normal embryonic development 
were applied first to mouse embryonic fibroblasts, and 
later to human-derived fibroblasts. Eight candidate factors, 
responsible for various developmental stages of MNs, in 
addition to 3 of the 5 general neural transcription factors, 
described previously, were inserted into mouse embryonic 
fibroblasts. Hb9-GFP was used to indicate motor neuron 
presence. Seven factors were deemed necessary to gener-
ate induced motor neurons (iMNs).  Using a patch-clamp 
technique, the resting membrane potential was found to 
be -49.5mV, very similar to ESC-derived MNs, which is -
50.5mV. Single and multiple trains of action potentials 
were elicited using a current-clamp technique in 90% of 
iMNs. The ability of iMNs to respond to typical inhibitory 
and excitatory neurotransmitters was then tested by expo-
sure to GABA, glycine and glutamate. The iMNs elicited 
normal functioning inhibitory and excitatory action poten-
tials upon contact with these neurotransmitters, indicating 
functional response of iMNs to neurotransmitters (Son, et 
al. 2011). 
 To determine the capability of iMNs to form func-
tional synapses with muscles, called neuromuscular junc-
tions, and to stimulate muscle contraction by release of 
ACh, iMNs and myotubes were co-cultured. Remarkably, 
the iMNs extended along the myotubes and after several 
days began inducing rhythmic contractions in the myo-
tubes. To determine whether the contractions were 
caused by ACh, curare was added to the culture. Curare is 
an antagonist of ACh and will inhibit ACh from binding to 
the ACh receptor site and stimulating muscle contrac-
tion.  After the curare was added the contractions stopped, 
indicating the ability of iMNs to develop and dispatch func-
tional ACh neurotransmitters capable of stimulating muscle 
contraction.  iMNs were then transplanted into the spinal 
cord of chick embryos to determine whether these cells 
can migrate to appropriate regions, survive and maintain 
function in vivo. Using Hb9-GFP, proper migration was ob-
served in the spinal cord of the embryo. Additionally, 80% 
of iMNs extended their axons out of the spine toward the 
musculature. The same methods were applied to human 
fibroblasts with similar results (Son, et al. 2011). These 
findings indicate the similarity of iMNs to ESC-derived MNs 
and the capability of MNs to function normally both in 
vitro and in vivo. 
 These studies determined the ability of differenti-
ated cells to be directly converted into specific subclasses 
of neurons, including motor neurons, skipping the induced 
pluripotent state. The use of oncogenes and tumorigenic 
factors are avoided, because the fibroblasts are not re-
quired to pass through an undifferentiated, ESC-like state.   
 
Results 
  
 In this study, 3 different stem cell therapies were 
presented and discussed, embryonic stem cells, induced 
pluripotent stem cells and direct reprogramming of differ-
entiated cells into neurons. All three therapies demonstrat-
ed the ability to produce functional motor neurons from 
stem cells in vitro and some in vivo (Miles, et al. 2004; Niz-
zardo, et al. 2013; Peljto, et al. 2010; Son, et al. 2011; 
Takahashi, Yamanka, 2006; Takahashi, et al. 2007; Um-
bach, et al. 2012; Vierbuchen, et al. 2010; Wichterle, et al. 
2002; Xu, et al. 2009; Yao, et al. 2013). Embryonic stem 
cells can successfully generate functional motor neurons 
using factors and signals found in normal embryonic devel-
opment (Miles, et al. 2004; Peljto, et al. 2010; Umbach, et 
al. 2012; Wichtelle, et al. 2002). Because of its ethical con-
troversy alternative methods are being researched. How-
ever, ESC-derived motor neurons remains a model for oth-
Stem Cells as a Cure For Amyotrophic Lateral Sclerosis  
36 
 
er research, such as induced motor neurons from pluripo-
tency and induced MNs from differentiated stem cells, be-
cause of its success in generating normal embryonic-like 
motor neurons. The induction of pluripotency from differ-
entiated stem cells demonstrated ESC-like character and 
could generate into functional neurons (Nizzardo, et al. 
2013; Takahashi, Yamanka, 2006; Takahashi, et al. 2007; 
Yao, et al. 2013). The significance of this method lies in its 
capability of using adult cells, as well as embryonic cells, to 
generate motor neurons (Takahashi, et al. 2007). Pluripo-
tency, however, is intricately linked to the oncogenic net-
work (Lee, et al. 2013). Many of the factors used to induce 
pluripotency are found in the regulation and maintenance 
of tumor formation (Lee, et al. 2013; Takashi, Yamanka, 
2006). These tumorigenic factors can potentially be pre-
served through the process of generating MNs and cause 
malignant teratomas when transplanted into humans (Lee, 
et al. 2013). Direct reprogramming of differentiated stem 
cells into motor neurons skips the pluripotent state and 
reduces the risk of tumorigenesis. These directly induced 
motor neurons can be generated from both embryonic and 
adult differentiated stem cells, with similar efficiency to 
ESC-derived MNs (Son, et al. 2011; Vierbuchen, et al. 
2010). This method can provide an ideal alternative to the 
controversial ESC-derived MNs and the tumorigenic iPSCs. 
 
Conclusion 
 
 Although the success of inducing motor neurons 
has been established preclinically, the safety and clinical 
efficiency of these stem cell therapies in human patients 
with ALS still have to be determined. Several clinical trials, 
conducted by “Neuralstem inc.,” “BrainStorm Cell Thera-
peutics,” and others, are currently underway to evaluate 
the safety of these methods. If safety can be determined, 
trials can begin to assess efficiency. While preclinical trials 
have been successful in generating motor neurons with 
proper function, clinical success may prove to be more 
difficult in ALS human patients. Since the etiology remains 
unknown, the degeneration initiating factors cannot be 
controlled and the new motor neurons may be subject to 
the same factors that caused the motor neuron degenera-
tion in the first place. To continue survival, frequent MN 
transplantations into ALS patients may have to take place 
each time degeneration reoccurs. While there are many 
clinical hurdles to overcome, with further research stem 
cell therapy can become the cure ALS patients have been 
waiting for.   
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er research, such as induced motor neurons from pluripo-
tency and induced MNs from differentiated stem cells, be-
cause of its success in generating normal embryonic-like 
motor neurons. The induction of pluripotency from differ-
entiated stem cells demonstrated ESC-like character and 
could generate into functional neurons (Nizzardo, et al. 
2013; Takahashi, Yamanka, 2006; Takahashi, et al. 2007; 
Yao, et al. 2013). The significance of this method lies in its 
capability of using adult cells, as well as embryonic cells, to 
generate motor neurons (Takahashi, et al. 2007). Pluripo-
tency, however, is intricately linked to the oncogenic net-
work (Lee, et al. 2013). Many of the factors used to induce 
pluripotency are found in the regulation and maintenance 
of tumor formation (Lee, et al. 2013; Takashi, Yamanka, 
2006). These tumorigenic factors can potentially be pre-
served through the process of generating MNs and cause 
malignant teratomas when transplanted into humans (Lee, 
et al. 2013). Direct reprogramming of differentiated stem 
cells into motor neurons skips the pluripotent state and 
reduces the risk of tumorigenesis. These directly induced 
motor neurons can be generated from both embryonic and 
adult differentiated stem cells, with similar efficiency to 
ESC-derived MNs (Son, et al. 2011; Vierbuchen, et al. 
2010). This method can provide an ideal alternative to the 
controversial ESC-derived MNs and the tumorigenic iPSCs. 
 
Conclusion 
 
 Although the success of inducing motor neurons 
has been established preclinically, the safety and clinical 
efficiency of these stem cell therapies in human patients 
with ALS still have to be determined. Several clinical trials, 
conducted by “Neuralstem inc.,” “BrainStorm Cell Thera-
peutics,” and others, are currently underway to evaluate 
the safety of these methods. If safety can be determined, 
trials can begin to assess efficiency. While preclinical trials 
have been successful in generating motor neurons with 
proper function, clinical success may prove to be more 
difficult in ALS human patients. Since the etiology remains 
unknown, the degeneration initiating factors cannot be 
controlled and the new motor neurons may be subject to 
the same factors that caused the motor neuron degenera-
tion in the first place. To continue survival, frequent MN 
transplantations into ALS patients may have to take place 
each time degeneration reoccurs. While there are many 
clinical hurdles to overcome, with further research stem 
cell therapy can become the cure ALS patients have been 
waiting for.   
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